We found that Akt inhibition was effective for anticancer effects when an Akt inhibitor was administered alone (ESE alone treatment group) or concomitantly with ESE (co-treatment group) and showed that the anti-cancer effects in the co-treatment group decreased compared with those in the other group, indicating that ESE-induced apoptosis can occur in a p53-dependent manner. Here, TP53 is linked to cancer.